TCRX (TScan) Forward P/E Multiple
The battle for medical leadership in T-cell therapy is driving growth, as reflected by the P/E forward valuation of TScan Therapeutics (TCRX) on this GURU.Markets platform chart, where 0.00 shows the current value of the metric. The business foundation is the TargetScan technology for creating personalized cancer drugs; however, the financial stability of TScan Therapeutics (TCRX) depends on test results and new investments.
Summary analytical data breakdowns for TScan (TCRX)
- current price and projected stock value:
- business market valuation indicators:
- book capitalization information:
- issuer credit burden and liquidity indicators:
Total Debt to Capital TScan Therapeutics|TCRX - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio TScan Therapeutics|TCRX - Company Cumulative Indebtedness|Debt to Book Capitalization Ratio TScan Therapeutics Inc|TCRX - Long-Term Debt Volume|Company Short-Term Debts TScan Therapeutics|Quick Ratio tscan.com
- financial results and valuation multiples details:
TCRX - Net Profit|Expected Profit TScan Therapeutics|TCRX - Price to Earnings Multiple|Projected Price to Earnings TScan Therapeutics|TCRX - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio TScan Therapeutics Inc|TCRX - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) TScan Therapeutics|TCRX - Earnings per share for the trailing year|Quarterly EPS earnings growth tscan.com|TCRX - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year TScan Therapeutics
Summary company analysis:TCRX TScan Therapeutics, Inc.
The development of personalized T-cell therapies at TScan Therapeutics (TCRX) requires colossal investments, making the company's forward P/E ratio a key indicator of capitalization relative to projected earnings. This metric daily compares the market value of shares with expected income, allowing investors to assess the maturation rate of the business model and confirm the fundamental stability of assets amidst infrequent reporting.
Main competitors
Projected Price to Earnings ONC (BeiGene)|HALO (Halozyme Therapeutics, Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple RVMD (RevMed)|AAPG - Projected Price to Earnings|CGON: Projected Price to Earnings|URGN - Forward P/E Multiple|Bicara Therapeutics (BCAX) - Future Price to Earnings|Personalis Inc - Future Price to Earnings Multiple|ERAS (Erasca Corp) - Forward P/E Multiple|Projected Price to Earnings Ratio Delcath Corp DCTH|Projected Price to Earnings YMAB (Y-mAbs Therapeutics)|Market Cap to Future Earnings Ratio AURA|Future Price to Earnings Candel Therapeutics, Inc. CADL|Market Cap to Projected Earnings Accuray Inc (ARAY)|SELLAS Life Sciences Group Inc. - Forward P/E Multiple|Actuate Therapeutics Inc (ACTU) - Projected Price to Earnings|CTOR: Forward P/E Multiple|TuHURA Biosciences (HURA) - Forward P/E Multiple|Future Price to Earnings Protara Therapeutics, Inc.|Price to Future Earnings Ratio FATE (Fate Therapeutics Inc)|Projected Price to Earnings WHWK (Aadi Bioscience Inc)|CSBR (championsoncology.com) - Future Price to Earnings Multiple|XBiotech - Projected Price to Earnings|Market Cap to Future Earnings Ratio CVM (CEL-SCI Corp.)|OS Therapies - Forward P/E Multiple|Future Price to Earnings Multiple RADX (radiopharmtheranostics.com)|ARTV: Forward P/E Multiple|Projected Price to Earnings Ratio Adlai Nortye (ANL)|Future Price to Earnings Veru Inc.|TPST: Future Price to Earnings Multiple|Forward P/E Multiple XLO|Forward P/E Multiple renovarobio.com (RENB)|Future Price to Earnings Mural Oncology MURA|KAPA (Kairos Pharma Limited) - Price to Expected Earnings Ratio|OnKure - Forward P/E Multiple|Projected Price to Earnings Ratio CytoMed Therapeutics|CRIS (curis.com) - Projected Price to Earnings|Apollomics (APLM) - Forward P/E Multiple|Projected Price to Earnings THAR|ADVB (Advanced Biomed Corp) - Market Cap to Future Earnings Ratio|Forward P/E Multiple GNPX|Market Cap to Projected Earnings calidibio.com|Forward P/E Multiple SBFM (Sunshine Biopharma, Inc.)|XBIO - Projected Price to Earnings|SLRX - Future Price to Earnings|Market Cap to Projected Earnings Kitov Pharma PPBT|AONC (aoncology.com) - Projected Price to Earnings|BGNE: Market Cap to Future Earnings Ratio|CKPT (Checkpoint Therapeutics, Inc.) - Forward P/E Multiple|Projected Price to Earnings elevationoncology.com (ELEV)|Future Price to Earnings iCAD, Inc. (ICAD)|IKNA (ikenaoncology.com) - Future Price to Earnings Multiple|Notable Labs, Ltd. - Projected Price to Earnings|VIRX: Price to Future Earnings Ratio|MorphoSys - Forward P/E Multiple|NAYA Biosciences Inc (NAYA) - Projected Price to Earnings|AAPGV: Forward P/E Multiple
